巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Compass Therapeutics

    CMPX
    3.060
    0.110
    3.73%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Compass Therapeutics - 延遲價格・最後更新於 16/08 9:30
    最高位
    3.060
    最低位
    2.920
    開市價
    --
    前收市價
    2.950
    成交量(千)
    0.14
    成交額(百萬)
    0.00
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    309.93
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    4.470 - 1.250
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Compass Therapeutics
    證券代碼
    CMPX.US
    所屬板塊
    Biotechnology
    公司業務
    Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. The company has drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases.
    發行量
    101302594
    公司總部
    80 Guest Street, Suite 601
    公司網址
    https://www.compasstherapeutics.com
    公司電郵
    vered.bisker@compasstherapeutics.com
    公司電話
    +1 617 500-8099
    暫無內容

    關於

    Compass Therapeutics(CMPX.US)所屬的行業板塊為Biotechnology。
    Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. The company has drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases.
    詳細公司背景可參考: https://www.compasstherapeutics.com